Ptc Therapeutics (PTCT) Non-Current Debt (2012 - 2025)

Ptc Therapeutics' Non-Current Debt history runs 12 years deep, the most recent figure standing at $286.0 million for Q2 2025.

• In Q2 2025, Non-Current Debt changed 0.42% year-over-year to $286.0 million; the TTM figure through Jun 2025 stood at $286.0 million (changed 0.42% YoY), while the FY2024 annual figure was $285.4 million, changed 0.42% from the prior year.
• Non-Current Debt was $286.0 million for Q2 2025 at Ptc Therapeutics, roughly flat from $285.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $573.2 million in Q3 2023 to a low of $281.6 million in Q3 2021.
• Historically, Non-Current Debt has averaged $364.3 million across 5 years, with a median of $285.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Debt soared 102.81% in 2022, then plunged 50.29% in 2023.
• A 5-year view of Non-Current Debt shows it stood at $281.9 million in 2021, then surged by 102.81% to $571.7 million in 2022, then slumped by 50.29% to $284.2 million in 2023, then gained by 0.42% to $285.4 million in 2024, then rose by 0.21% to $286.0 million in 2025.
• The last three Non-Current Debt figures came in at $286.0 million (Q2 2025), $285.7 million (Q1 2025), and $285.4 million (Q4 2024), per Business Quant data.